Corporate Update re development of new test Q1 could be any day now but at latest Dec 30.
I sincerely hope investors recieve an update on the development of a new test, regardless of what stage of validation the company is in. A dual Antigen/Antibody test would be a game changer, and MIR's RVF technology gives it the greatest chance at success.
In terms of revenues for Q1, I am expecting at minimum production/sale of 20,000 units per week for $2.4 million. I think 50,000 units a week is possible, for $6 million in revenue but this would be excellent in my view given that automation is still happening. There is potential for even higher revenues considering the growth in licensing revenue last quarter... will be interesting to see if there is growth in this area (pure profit/recovery of prior R&D $).